The Natural History of thyroid disease in patients with longstanding rheumatoid arthritis (RA) reflects the complex interactions between chronic autoimmune inflammation, genetic susceptibility, shared immune pathways, and long-term treatment effects. As RA progresses over years, patients become increasingly prone to developing thyroid disorders—most commonly autoimmune thyroid disease (AITD) such as Hashimoto thyroiditis, subclinical hypothyroidism, or, less frequently, Graves’ disease. Thyroid dysfunction in RA often begins silently. Many individuals initially develop thyroid autoantibodies (anti-TPO, anti-TG) long before clinical symptoms appear. Over time, persistent immune activation—especially involving Th1, Th17, B-cell hyperactivity, and pro-inflammatory cytokines such as IL-6 and TNF-α—contributes to progressive thyroid tissue damage. This leads to structural changes such as diffuse enlargement, lymphocytic infiltration, or the formation of thyroid nodules. As RA becomes longstanding, metabolic and inflammatory abnormalities further affect thyroid hormone metabolism. Chronic inflammation reduces peripheral conversion of T4 to T3, resulting in low-T3 levels, especially during active disease flares. Some RA medications, particularly glucocorticoids and biologic agents, can modify thyroid function: steroids may blunt TSH secretion, while biologics (such as TNF-α or B-cell inhibitors) may reduce thyroid autoimmunity in some patients. Clinically, thyroid dysfunction may remain subclinical for years. When symptoms emerge—fatigue, weight changes, cold intolerance, mood disturbances—they often overlap with RA symptoms, causing underdiagnosis or misinterpretation. Without regular monitoring, many patients progress from subclinical to overt hypothyroidism. Hyperthyroidism, while less common, can worsen joint inflammation, cardiovascular strain, and metabolic imbalance. Long-term consequences of untreated thyroid disease in RA include increased cardiovascular risk, worsening functional outcomes, reduced responsiveness to DMARDs, poorer quality of life, and heightened systemic complications. Early detection through routine thyroid function testing and ultrasound evaluation is essential for preventing progression and improving overall health outcomes. In summary, the natural history of thyroid disease in longstanding RA is characterized by early immune sensitization, gradual structural and functional thyroid impairment, medication-modified progression, and increasing clinical significance over time. Continuous monitoring and timely intervention play a crucial role in optimizing long-term patient care.